Related Experiment Video

Updated: Jun 23, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K

Androgen receptor, PARP signaling, and tumor microenvironment: the 'perfect triad' in prostate cancer?

Marianna Garofoli1, Brigida Anna Maiorano2, Giuseppina Bruno1

  • 1Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy.

Therapeutic Advances in Medical Oncology
|June 18, 2024
PubMed

Insights

Poly-ADP-ribose polymerase (PARP) inhibitors show promise for prostate cancer (PCa) patients with DNA repair defects. Research explores combining PARP inhibitors with other therapies to overcome resistance and expand treatment benefits for more PCa patients.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Aberrations in homologous recombination repair (HRR) pathway are present in prostate cancer (PCa).
  • PARP inhibitors (PARPi) are effective in PCa patients with HRR defects, especially those with BRCA1/2 alterations.
  • Expanding PARPi benefits to patients without detectable HRR alterations is an active area of research.

Purpose of the Study:

  • To review the current use of PARPi in prostate cancer.
  • To explore potential synergies between PARPi and other molecular pathways, including androgen receptor signaling inhibitors and immune checkpoint inhibitors.
  • To identify unanswered questions regarding PARPi use, patient selection, combination strategies, and resistance mechanisms.

Main Methods:

  • Review of preclinical and clinical studies on PARPi in prostate cancer.
  • Analysis of potential synergistic effects of PARPi with other therapeutic agents.
  • Evaluation of resistance mechanisms, including the role of the tumor microenvironment.

Main Results:

  • PARPi prolong survival in PCa patients with HRR defects.
  • Investigating combinations of PARPi with androgen receptor signaling inhibitors and immune checkpoint inhibitors is ongoing.
  • Resistance mechanisms, including immunosuppressive tumor microenvironment, can hinder treatment effectiveness.

Conclusions:

  • PARPi represent a significant therapeutic strategy for prostate cancer, particularly in HRR-deficient tumors.
  • Optimizing combination therapies and identifying patient populations that benefit most from PARPi are crucial next steps.
  • Further research is needed to address resistance mechanisms and refine treatment strategies for broader application of PARPi in PCa.
Keywords:
DNA damage repairPARP inhibitorandrogen receptorimmune checkpoint inhibitor

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K